Silence Therapeutics PLC (SLN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.38 (-2.52%), Market cap $0.29B, 52-week low–high $4.30 ~ $7.97.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc
Financial statements, price targets, institutional (13F) holdings and related news for Silence Therapeutics PLC are updated in real time on BlackAll Trade.
Silence Therapeutics PLC trades at $12.38 (-2.52%). Real-time quotes and charts are available on BlackAll Trade.
Silence Therapeutics PLC has a market cap of about $0.29B.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of spe